PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Bipolar Disord. Author manuscript; available in PMC Mar 1, 2014.
Published in final edited form as:
PMCID: PMC3582727
NIHMSID: NIHMS423948
Gene expression alterations in bipolar disorder postmortem brains
Haiming Chen,a Nulang Wang,b Xin Zhao,b Christopher A Ross,cd K Sue O’Shea,e and Melvin G McInnisa
aDepartment of Psychiatry and Comprehensive Depression Center, University of Michigan Medical School, Ann Arbor, MI
bMolecular and Behavioral Neuroscience Institute, University of Michigan Medical School, Ann Arbor, MI
cDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
dDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD
eDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, USA
Corresponding author: Melvin G. McInnis, M.D., Department of Psychiatry and Comprehensive Depression Center, University of Michigan Medical School, 4250 Plymouth Road, Ann Arbor, MI 48109, USA, Fax: 734-936-2690, mmcinnis/at/umich.edu
Objectives
Bipolar disorder (BD) is a mental illness of unknown neuropathology and has several genetic associations. Antipsychotics are effective for the treatment of acute mania, psychosis, or mixed states in BD individuals. We aimed to identify gene transcripts differentially expressed in postmortem brains from BD individuals in both the antipsychotics-exposed (exposed) and non-exposed groups and controls.
Methods
We quantified the abundance of gene transcripts in postmortem brains (brains) of seven exposed, seven non-exposed, and 12 controls with the Affymetrix U133P2 GeneChip microarrays and technologies. We applied a q-value of ≤ 0.005 to identify statistically significant transcripts with mean abundance differences between non-exposed and controls (and/or exposed).
Results
We identified 2,191 unique genes with significantly altered expression levels in non-exposed brains compared to those in the control and exposed groups. The expression levels of these genes were not significantly different between exposed and controls, suggesting a normalization effect of antipsychotics on the expression of these genes. Gene Ontology (GO) enrichment analysis showed significant (Bonferroni p ≤ 0.05) clustering of subgroups of the 2,191 genes under a broad number of GO terms, noticeably the protein products of genes enriched are critical to the function of synapses, including intracellular protein trafficking, synaptic vesicle biogenesis, transport, releasing and recycling, as well as organization and stabilization of the node of Ranvier.
Conclusions
These results support a hypothesis of synaptic and intercellular communication impairment in BD. The apparent normalization of expression patterns with exposure to antipsychotic medication may represent a physiological process that relates both to etiology and improvement patterns of the disorder.
Keywords: antipsychotics, microarray, synapse, transport
Bipolar disorder (BD) is a chronic, severe psychiatric illness characterized by recurrent pathological swings of mood between mania and depression, often with catastrophic social, personal, medical, or vocational consequences. It is generally a lifetime diagnosis, with significant heterogeneity, that begins in late adolescence or early adulthood with variability in presentation, symptomatology and course of illness (1). The genetic predisposition to the illness and high heritability is observed clinically in family, twin, and adoption studies (24), and genetic linkage and association studies have found numerous modest risk loci for BD (5), consistent with a complex mode of inheritance in BD (6, 7). The currently reported genetic variants with modest odds ratios (1.1–1.3) cannot account for the high heritability of the disorder; additional approaches beyond population genetics will be needed to understand the etiology of BD.
Gene expression analyses have used microarray technology to identify gene transcripts differentially expressed in postmortem brains or nucleated peripheral blood cells from BD affected individuals in comparison to healthy controls (816). Although these studies have identified sets of genes differentially expressed between BD samples and controls (Supplementary Table 1), each significant gene set identified was generally limited to a corresponding individual study. Few overlapping changes were consistent among the extant expression studies.
A recent meta-analysis performed on 12 microarray data sets was performed to address the lack of consensus between studies (17), the results suggested that inconsistency between microarray studies was due to small sample size, overly restrictive or overly broad criteria for assigning of significance, as well as lack of consistent statistical adjustment for confounding effects. Meanwhile, the meta-analysis did identify 375 genes with significantly altered expression patterns in BD brains contrasting to controls. Many genes identified in this analysis are functionally related to energy processing, supporting an energy processing dysfunction hypothesis in BD (10, 17).
Given the complex inheritance of BD and the current progress in gene mapping and expression analyses, we reason that findings from each independent study are likely to partially contribute to understanding the molecular basis of the illness. The integration and comparison of results from independent studies may prove helpful in the identification of genes and pathways for prioritization of deeper analyses. We compared the abundance of gene transcripts in brain samples from deceased individuals diagnosed with BD and unrelated controls, and identified transcripts with altered expression levels in BD brains (including many previous reported significant genes). When we used exposure to antipsychotic medication as a variable we find evidence that antipsychotics normalize the expression levels of genes in BD brains to near control levels.
Postmortem brain samples
Postmortem brain samples (brains) were obtained from the Stanley Medical Research Institute (SMRI) neuropathology consortium (18). All brains were collected using IRB-approved protocols for postmortem tissue collection and later provided to qualified investigators for analysis. The consortium consists of 15 brains of each BD, schizophrenia, major depression, and healthy control groups. All brains were matched by gender, age, race, postmortem interval (PMI), brain pH, side of the brains, and excluded neuropathological abnormalities. We analyzed the BD (n = 15) and normal control brains (n = 15) in this study (Tables 1 and and2).2). The tissue sample was derived from the premotor cortex (Brodmann’s area 6). Due to poor RNA quality, three samples (two controls and one BD) were not processed for microarray GeneChip hybridization. Medication history indicated that half of the 14 BD brains included in microarray analysis were on antipsychotics exposure at time of death (Tables 1 and and22).
Table 1
Table 1
Demographics of postmortem brains from the Stanley Medical Research Institute (SMRI) neuropathology consortiuma (see Table 2 for other medications)
Table 2
Table 2
Demographics of postmortem brains from the Stanley Medical Research Institute (SMRI) neuropathology consortiuma
RNA extraction
Total RNA was isolated from 200 mg of frozen tissue using the TRIzol reagent (Cat #15596-026, Invitrogen, Grand Island, NY, USA). All RNA samples were then treated with RNase-free DNase (Cat #79254, Qiagen, Valencia, CA, USA), followed by a cleanup step with the RNeasy MinElute Cleanup reagents (Cat #74204, Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA quantity was determined using a ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). One microgram of RNA from each sample was applied to 1% agarose gel electrophoresis to examine RNA integrity and potential DNA contamination. The RNA samples were stored at −80° C until microarray analysis.
Microarray platforms and data acquisition
The GeneChip U133 plus 2.0 (U133P2) microarrays (Affymetrix, Santa Clara, CA, USA) were used for expression analysis of RNA from postmortem brains. Affymetrix microarray hybridization was carried out at the Johns Hopkins Medical School microarray core facilities. Image processing and scaling for normalization were carried out using GCOS1.1 software (Affymetrix). Standard Affymetrix microarray quality controls were employed including: scaling factor, noise, background, percentage of present calls, 5′/3′ signal ratios observed in the GAPDH messenger RNA (mRNA), and the 5′/3′ signal ratios of spiking genes. There were no significant differences between BD and control groups in the variances of scaling factors, present calls, and 3′/5′ signal ratios of GAPDH (data not shown). One brain sample coded UK-1.41 (SMRI sample code) had a 3′/5′ signal ratio of GAPDH 4.64 that was greater than an adequate threshold of three for brain tissue (19); therefore, was removed from statistical analysis. Data that passed these quality control measures were then used in differential expression analyses. Thus, a total of 26 microarray profiles (14 BD, 12 controls) were included in statistical analysis of differential gene expression.
Microarray data analysis
For analysis of the U133P2 microarray data, we processed raw data (CEL files) using the Bioconductor package ‘Affy’ for R (20, 21). We used the Affy RMA (Robust Multichip Average) algorithms for background adjustment, probe intensity summarization, and normalization. Log2 transformed probe intensity RMA values were used in differential gene expression analysis.
We classified the postmortem brains into three groups (Tables 1 and and2):2): (i) BD patients who were treated with antipsychotics at time of death and during their life time (exposed group, n = 7); (ii) the non-exposed were brains from BD patients who were never treated with antipsychotics (non-exposed group, n = 7); and (iii) normal controls (n = 12). This strategy in data analysis is different from simple case–control comparison performed in published studies using the neuropathology consortium sample from SMRI (Supplementary Table 1). Other medications were generally equally distributed between the two BD groups.
We used the Significant Analysis of Microarrays (SAM) software package for Microsoft Office Excel (22) for statistical analysis to identify genes that were significantly differentially expressed. We strategically fitted the multi-class algorithms of SAM with data from the three groups. We found that the exposed profiles were very similar to that of the controls; the differences among the three groups were mostly contributed by the non-exposed group. We therefore performed a SAM two-class analysis between the non-exposed and the rest profiles (exposed plus controls) to identify and report differentially expressed genes.
The transcript sequences in NCBI’s UniGene, dbEST, GenBank, and Refseq databases were used to design the U133p2 GeneChip. The current annotation of these sequences is incomplete. We therefore only focused on the analysis of probe sets with NCBI’s Refseq annotation.
We used SAM q-values [equivalent to false discovery rate (FDR)] of 0.005 as cut off points to call significant genes. Since the correlation between fold change (FC) and functional impact empirically remains unknown, we did not apply a FC cutoff point to exclude any significant calls.
Real-time quantitative RT-PCR validation of microarray results
Verification of microarray results was performed with TaqMan qRT-PCR (23) using an ABI 7900HT Sequence Detection System (ABI, Foster City, CA, USA). Two micrograms of total RNA from each sample was converted to first strand cDNA using the Superscript first-strand cDNA synthesis system following the manufacturer’s instructions (Cat #18089-011, Carlsbad, CA, USA). The cDNA stocks were then diluted 50-fold with distilled deionized water. TaqMan assays were performed in 20-μl reactions in 384-well format plates, each containing 10 μl of 2 × TaqMan Master Mixture, 1 μl of 20x primers/probe, and 9 μl of 50-fold diluted first strand cDNA templates. The ribosomal protein S16 (RPS16) gene that did not exhibit significant variation in expression between samples was used as an endogenous control. The Assays on Demand (AOD) for seven brain-expressed genes were purchased from Applied Biosystems (ABI, Foster City, CA, USA). We used the 2−ΔΔCt method (24) to calculate fold changes using the threshold cycle value (Ct) in the samples of non-exposed and controls after normalizing to the Ct values of the internal reference RPS16. For significance testing, two-tailed t-tests were employed.
Gene Ontology (GO) term enrichment analysis
We used the stand alone expression analysis systematic explorer (EASE) software for GO term enrichment and pathway analysis (25). We used the NCBI’s Refseq genes as the background list. The 2,022 unique genes (excluding 169 pH related transcripts) from the significant list were used as input against the background genes for EASE to identify genes specifically enriched in either the GO biological process system, molecular function system, or KEGG pathways (26). Significantly enriched GO terms were those with a Bonferroni p of ≤ 0.05.
Differential gene expression in brains from individuals with BD contrasted with controls
A large number of genes were differentially expressed in non-exposed brains. Using the SAM multi-class algorithm (22) we identified 3,376 gene transcripts differentially expressed between the non-exposed, exposed, and control groups (q-value ≤ 0.05, equivalent to FDR). At a q-value ≤ 0.01 cutoff, 1,184 unique genes represented by 1,419 probe sets were differentially expressed among the three groups (Supplementary Fig. 1). We observed that the expression levels of these significant transcripts in the exposed brains were very similar to those of controls; the significant differences were largely contributed by the non-exposed group (Supplementary Fig. 1). This observation suggests that antipsychotics have considerable effects on gene expression, and that they appear to normalize the differentially expressed genes in BD brains to the mean levels of controls.
Since the exposed profiles were very similar to, and highly correlated with those of controls (Supplementary Fig. 1), we combined those groups and then compared them with the non-exposed group using the SAM two-class algorithms. We identified 2,191 unique transcripts (2,818 probe sets) differentially expressed in the non-exposed brains (q ≤ 0.005) (Fig. 1). Among these 2,191 transcripts, 116 showed increased, and 2,075 decreased in mean abundance level in the non-exposed contrasted to that of the combined group (Supplementary Table 2). There was high concordance between the multi-class and two-class analyses, with only 1.96% of the 2,191 significant genes not identified by SAM multi-class analysis (not shown). The two-class analysis achieved a much lower q-value (≤ 0.005) for the 2,191 significant genes.
Fig. 1
Fig. 1
Scatter plot illustrating the mean difference in log2 ratio (M) versus the average expression level in log2 average (A) for each of the genes analyzed. The yellow line indicates no difference in mean expression levels. A two-fold mean difference (log (more ...)
We also observed that most of the 2,191 significant genes identified showed modest mean expression level changes (< 2 fold). This is consistent with published data (Supplementary Table 1). The minimum exposed versus control fold change was −1.09-fold, and maximum −4.5-fold. We also identified multiple significant transcript variants from the same gene detected by corresponding probe sets (Supplementary Table 2).
Antipsychotic treatment normalizes gene expression in BD brains
We found that the mean levels of the significant transcripts were similar between the exposed brains and controls (Supplementary Fig. 1). For instance, in the non-exposed brains the mean abundance of RGS4, BAG3, and SYN2 transcripts showed greater than two-fold change compared to that of the combined samples, but no significant difference between the exposed and controls (Fig. 2). This is of potential relevance as RGS4, BAG3, and SYN2 have been implicated in psychiatric illnesses (27, 28) or in the central nervous system in response to antipsychotic treatment (2931).
Fig. 2
Fig. 2
A boxplot shows three messenger RNA (mRNA) species encoding BAG3, RGS4, and SYN2 differentially expressed between exposed, controls, and non-exposed. Shown on the y-axis is the measured expression levels of the genes in log2 value, on the x-axis are the (more ...)
Real-time quantitative PCR validation
Real-time qRT-PCR was employed to validate seven randomly selected significant genes using cDNAs derived from total RNA extracted from the non-exposed and controls. The TaqMan results confirmed our microarray findings for all seven genes (Table 3). The changes were not correlated with age, gender, brain pH, or postmortem interval.
Table 3
Table 3
TaqMan analysis of differential gene expression between non-exposed brains and controls
Gene Ontology term enrichment analysis revealed functional themes
EASE analysis excluded 169 unique genes known to be related to low brain pH (10, 15, 32). There was significant enrichment of genes in one KEGG pathway, as well as 18 Biological Process terms and 11 terms of Molecular Function (Bonferroni p ≤ 0.05) (Supplementary Table 3). Significant GO terms of biological processes presented a theme of protein metabolic process, transport, localization, post-translational protein modification, protein folding, and synaptic transmission. Significant GO terms of molecular function identified protein and nucleotide categories including ATP binding, ligase, and catalytic activities. Interestingly, long-term potentiation was the one significant KEGG pathway identified in this analysis.
We found that multiple members of gene families were often enriched under corresponding GO terms. For examples, 13 genes encoding multiple subunits of adaptor-related protein (AP) complexes (AP1M1, AP1S1, AP1S2, AP2A1, AP2A2, AP2B1, AP2M1, AP2S1, AP3B2, AP3M2, AP4B1, AP4M1, and AP4S1) were enriched under the term intracellular transport; and six genes encoding eukaryotic translation initiation factors (EIF2B3, EIF2B5, EIF2S1, EIF4E, EIF4G2, and EIF5) were enriched under GO term protein metabolic process. Although no direct evidence relates any of the AP subunits to bipolar disorder, AP complexes are critical proteins in synaptic vesicle formation and transport (33). Multiple BD risk factors have been proposed to interrupt protein synthesis via the translation initiation complex EIF2B (34). Our data implicate the functionally related genes encoding proteins involved in neurotransmitter biosynthesis, or protein synthesis and modification, however postmortem data such as these cannot determine if there are causal or consequential relationships between disease, pharmacological intervention, and observed gene expression changes. This will require cellular models that can be studied prospectively.
We examined the gene expression profiles of a postmortem brain sample well matched by gender, age, postmortem interval, pH, side of the brain, and race (18). We identified 2,191 unique genes (FDR ≤ 0.005) differentially expressed in the premotor cortex of BD individuals not exposed to antipsychotics at time of death or during their lifetime compared to exposed brain and controls. We observed that in exposed brains the expression levels of these genes were similar to that of controls (diminished statistical significance). This suggests that antipsychotics may ‘normalize’ (or at least suppress differences in) the expression levels of several genes relevant to the molecular pathophysiology of BD. This broad effect on gene expression of the antipsychotics may be one of several factors that reflect the significant heterogeneity of the illness and includes pharmacogenomics and pharmacodynamics
The normalization effect of antipsychotics is supported by a recent report using induced pluripotent stem cell (iPSC)-derived neurons to model schizophrenia (35). This study identified signaling pathways that were abnormal in cells derived from individuals with schizophrenia, that could be ameliorated by treatment with a typical antipsychotic medication, loxapine (35). While the outcome of gene expression modulation through antipsychotic medication is common to the current study and an iPSC-derived model of schizophrenia, there are clearly many confounds from the environment that affect the adult postmortem brain. Medication is one of many tools to alter the environment at defined stages, the results of which may have causal relevance to either the illness or the neuropharmacology of the medication.
Using their method of convergent functional genomics, Le-Niculescu and colleagues (36) generated a list of 1,529 genes implicated in BD or depression. In a study of genomic variation for schizophrenia, Lee and colleagues (37) reported 2,725 genes containing common SNPs (single nucleotide polymorphisms) that captured a significant proportion of the variance in liability to schizophrenia. Other common conditions have many genes implicated: e.g., thousands of genes were found to change expression levels in response to viral infection in peripheral blood mononuclear cells using integrative personal ‘omics’ profiling (38).
In comparing our significant genes with the 375 significant genes identified in the meta-analysis of 12 microarray data sets (17), 185 genes were common to both lists (Fisher’s exact test p ≤ 0.015), and 99% of these common changes were in the same direction (mostly down-regulated) (Supplementary Table 4). The significant overlap suggests high concordance between this current study and the meta-analysis. It also implies there may be common aspects of pathophysiology in some brain regions, since the current study was performed on tissue from the BA6 region, while the meta-analysis (17) combined profiles from different brain regions (mainly BA6, 9, 10, 46) from 12 studies including our microarray raw data.
A recent microarray analysis of the thalamic transcriptome performed on material from the SMRI Neuropathology Consortium identified 72 genes with highly significantly altered expression levels in bipolar brains (15). Of these, we found that 22 genes were common to our study (Fisher’s exact test p = 2.14 × 10−6) and all common changes were in the same directions (two increased and 20 decreased) (Supplementary Table 5). This comparison is reasonably sound since both experiments were performed on the U133P2 Genechips and tested similar number of probe sets (around 22,000).
It remains a challenge to identify causative alterations in gene expression using microarray data of postmortem tissues. We observed 86 genes that showed two-fold or greater difference in mean expression levels between BD brains and the combined group, for example, RGS4, BAG3, and SYN2 showed two-fold or greater changes (see Fig. 2). RGS4 (regulator of G protein signaling 4) has been associated with schizophrenia (39) and implicated in BD (40). Though BAG3 has not been previously implicated in BD, it has been identified with relevant expression changes in response to antipsychotic treatment in animal brain (29). SYN2, a gene involved in synaptic function, has been associated with BD in a functional analysis of extant data (41). Given the assumption that larger fold changes have stronger functional impact, priorities may be given to the genes with higher magnitude changes for further detailed analysis.
Functional GO term enrichment analysis identified significant clusters of genes under several biological process, including protein metabolic process, protein transport, macromolecule localization, protein localization, intracellular protein transport, establishment of protein localization, post-translational protein modification, protein folding, molecular function, vesicle-mediated transport, synaptic transmission, and intracellular transport; or GO terms of molecular function involve protein binding, nucleotide/ribonucleotide including ATP binding, ligase and catalytic activities. These data and neuropathological studies of BD brain suggest that as in neurodegenerative conditions, protein processing and transport may be significantly altered.
The enriched genes under specific GO terms often include multiple members of gene families. For example, five members of the disintegrin and metalloprotease (ADAM) gene family, ADAM10, ADAM11, ADAM15, ADAM17, and ADAM23, were in enriched under the GO term protein metabolic process. The ADAM genes encode membrane-anchored proteins that have been shown to play important roles in the development of the nervous system, including regulation of proliferation, migration, differentiation and survival of various cells, as well as axonal growth and myelination (42). Enriched under the GO term protein transport were 13 members of adaptor-related protein complex (AP) gene families: AP1M1, AP1S1, AP1S2, AP2A1, AP2A2, AP2B1, AP2M1, AP2S1, AP3B2, AP3M2, AP4B1, AP4M1, and AP4S1. AP complexes, AP-1, AP-2, AP-3, and AP-4, play important roles in synaptic vesicle formation and endocytosis (33). The expression levels of these genes are significantly lower in non-exposed brains compared to controls, suggesting a hypothesis of synapse impairment in BD. How these genes may be involved in BD is currently unknown, and awaits analysis in relevant cellular models.
A number of ‘high profile’ genes previously implicated in BD also stand out in our study. For example, the mRNA levels of GSK3B, FKBP5, ANK3 genes were altered in the non-antipsychotic medication brains. Glycogen synthase kinase 3 beta (GSK3β) is a known target of lithium, and has been hypothesized to be the molecular basis of lithium treatment of BD (43). FK506 binding protein 51, the protein product of the FKBP5 gene, forms part of a complex with the glucocorticoid receptor and can modulate cortisol-binding affinity (44). Variations in FKBP5 have been reported to be associated with BD (45).
The ANK3 gene product, Ankyrin-G, is present at the axonal initial segment and at nodes of Ranvier. Ankyrin-G plays key roles in node formation and function in the central and peripheral nervous systems. Genome wide association analysis identified single nucleotide polymorphisms at the ANK3 locus associated with BD (46), and cis-acting variations in the ANK3 locus were shown to affect its expression (47). In addition to ANK3, several genes encoding key components of node of Ranvier or paranodal region, such as NRCAM, SCN8A, KCNQ2, SPTBN4, CNYN1, EPB41L3, and ANK2, are among the list of genes identified in this study (Supplementary Table 2). These observations suggest node impairment may be a neural mechanism of BD.
The limitations of the current analysis relate primarily to the relatively small number of individuals in the study of postmortem samples. It would be useful to replicate these findings in additional samples and studies; however, there is considerable overlap in the genes identified in the current study with those from previous studies (15, 17). There are many confounding factors that essentially limit the utility of postmortem gene expression analyses which include sex-dependent expression differences, death and agonal factors including the postmortem interval and tissue pH. The postmortem brain most likely reflects the end-stage organ disease state and may not reflect the initial etiological mechanisms of the disorder. There are several options for study design and include: (i) the ascertainment and procurement of additional postmortem brains for study and (ii) the establishment of cellular models that are derived from individuals with BD from whom there are considerable phenotypic and longitudinal data that may be factored into the analyses. Clearly, the second option is the ideal option. Individuals with BD that have common phenotypic features may be ascertained and samples, the cell lines grown under controlled conditions of exposure to environmental perturbations (medications and other biological variations) and measured consistently. Cellular models range from iPSC-derived neurons to cells derived from B lymphocytes transformed with EBV. The consistent feature being cellular tissue derived from an individual with the disorder. The limitations of the cellular models are the lack of ability to study the complex circuitry of the human brain, however complex biochemical pathways could be studied at a sophisticated biological level to determine interactive correlates between pathways.
In summary, we identified a large number of genes with altered expression in BD brains not exposed to antipsychotics. These changes are normalized to the levels of healthy controls and BD brains treated with antipsychotics. Functional GO terms analysis suggests a theme that these gene products are involved in neuronal communication that may be impaired in BD brains. Although our current results are concordant with previous findings, a caveat exists in interpreting of data generated from postmortem brains that are further confounded by agonal status, tissue pH, postmortem interval, medication, etc. Neuropsychiatric and neurological diseases are increasingly thought to be developmental in nature, and the fact that disease-specific changes are unlikely be distinguished from confounders in postmortem brains, combine to suggest that disease-specific live neurons are critically required to study the molecular basis of BD and to assemble a palette of disease-causing genes. This goal will be achieved in the systematic study of live neurons derived from iPSCs (48) or from differentiated easily accessible tissue of non-neural origin (35, 49).
Supplementary Material
Supp FigureS1
Supp TableS1
Supp TableS2
Supp TableS3
Supp TableS4
Supp TableS5
Supplementary legends
Acknowledgments
This study was supported by grants from the National Institute of Health (NIH) (K01 MH064596-02) and from NARSAD with Young Investigator Award to HC (2003–2005), by the University of Michigan Comprehensive Depression Center Rachel Upjohn Clinical Scholars Award to HC (2007), and by Stanley Medical Research Institute with research grant to HC (2005). MGM and HC are supported by the Heinz C. Prechter Bipolar Genetics Funds at the University of Michigan, and NIH grants (MH070775, U54-DA-021519). Part of the work was carried out in the Consortium for Stem Cell Therapies Core laboratory and also supported by the A. Alfred Taubman Medical Research Institute.
We are grateful to Drs. Fan Meng and James Cavalcoli at the NCIBI for providing assistance in bioinformatics analysis. Special thanks to Drs. Aravinda Chakravarti, Johnatan Pervsner, Forrest Spencer, and Terry Betty for supporting HC’s career development and consultation in microarray analysis. We thank Francisco Martínez Murillo at the Johns Hopkins University Medical School microarray core laboratory for Genechip hybridization analysis. We thank Dr. John Greden, Executive Director of the University of Michigan Depression Center and Dr. Gregory Dalack, Chairman of the University of Michigan Department of Psychiatry for supporting this project. The Stanley Medical Research Institute provided the postmortem brain samples.
Footnotes
Disclosures
The authors of this paper declare no potential conflicts of interest in connection with this manuscript.
1. Goodwin FK, Jamison KR. Manic Depressive Illness. Oxford University Press; New York: 1990.
2. Gershon ES, Hamovit J, Guroff JJ, et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch Gen Psychiatry. 1982;39:1157–1167. [PubMed]
3. Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive disorders. Br J Psychiatry. 1977;130:330–351. [PubMed]
4. Mendlewicz J, Rainer JD. Adoption study supporting genetic transmission in manic--depressive illness. Nature. 1977;268:327–329. [PubMed]
5. Serretti A, Mandelli L. The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions. Mol Psychiatry. 2008;13:742–771. [PubMed]
6. Craddock N, Khodel V, Van EP, Reich T. Mathematical limits of multilocus models: the genetic transmission of bipolar disorder. Am J Hum Genet. 1995;57:690–702. [PubMed]
7. Crow TJ. How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry. 2007;164:13–21. [PubMed]
8. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry. 2004;9:406–416. [PubMed]
9. Jurata LW, Bukhman YV, Charles V, et al. Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods. 2004;138:173–188. [PubMed]
10. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241–253. [PubMed]
11. Tsuang MT, Nossova N, Yager T, et al. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;133:1–5. [PubMed]
12. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry. 2006;11:965–978. [PubMed]
13. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005;102:15653–15658. [PubMed]
14. Bousman CA, Chana G, Glatt SJ, et al. Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:494–502. [PubMed]
15. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. J Hum Genet. 2009;54:665–675. [PubMed]
16. Choi KH, Higgs BW, Wendland JR, Song J, McMahon FJ, Webster MJ. Gene expression and genetic variation data implicate PCLO in bipolar disorder. Biol Psychiatry. 2011;69:353–359. [PMC free article] [PubMed]
17. Elashoff M, Higgs BW, Yolken RH, et al. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci. 2007;31:221–243. [PubMed]
18. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res. 44:151–155. 20003. [PubMed]
19. Popova T, Mennerich D, Weith A, Quast K. Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues. BMC Genomics. 2008;9:91. [PMC free article] [PubMed]
20. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264. [PubMed]
21. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307–315. [PubMed]
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–5121. [PubMed]
23. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′—3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 1991;88:7276–7280. [PubMed]
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed]
25. Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70. [PMC free article] [PubMed]
26. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. [PMC free article] [PubMed]
27. Prasad KM, Almasy L, Gur RC, et al. RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample. Schizophr Bull. 2010;36:983–990. [PMC free article] [PubMed]
28. Dean B, Boer S, Gibbons A, Money T, Scarr E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry. 2009;22:154–160. [PubMed]
29. Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry. 2010;67:263–269. [PubMed]
30. Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:64–68. [PubMed]
31. Thomas EA. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol. 2006;34:109–128. [PubMed]
32. Li JZ, Vawter MP, Walsh DM, et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet. 2004;13:609–616. [PubMed]
33. Danglot L, Galli T. What is the function of neuronal AP-3? Biol Cell. 2007;99:349–361. [PubMed]
34. Carter CJ. eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia? Schizophr Bull. 2007;33:1343–1353. [PMC free article] [PubMed]
35. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221–225. [PMC free article] [PubMed]
36. Le-Niculescu H, Patel SD, Bhat M, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:155–181. [PubMed]
37. Lee SH, DeCandia TR, Ripke S, et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet. 2012;44:247–250. [PMC free article] [PubMed]
38. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293–1307. [PMC free article] [PubMed]
39. Craddock N, O’Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet. 2005;42:193–204. [PMC free article] [PubMed]
40. Li Y, Zhao Q, Zhang Z, et al. Association study between RGS4 and bipolar disorder in the Chinese Han population. Psychiatr Genet. 2010;20:130–132. [PubMed]
41. Le-Niculescu H, Balaraman Y, Patel S, et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:129–158. [PubMed]
42. Yang P, Baker KA, Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol. 2006;79:73–94. [PubMed]
43. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4:117–128. [PubMed]
44. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34 (Suppl 1):S186–S195. [PubMed]
45. Willour VL, Chen H, Toolan J, et al. Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry. 2009;14:261–268. [PubMed]
46. Ferreira MA, O’Donovan MC, Meng YA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40:1056–1058. [PMC free article] [PubMed]
47. Quinn EM, Hill M, Anney R, Gill M, Corvin AP, Morris DW. Evidence for cis-acting regulation of ANK3 and CACNA1C gene expression. Bipolar Disord. 2010;12:440–445. [PubMed]
48. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. [PubMed]
49. Pang ZP, Yang N, Vierbuchen T, et al. Induction of human neuronal cells by defined transcription factors. Nature. 2011;476:220–223. [PMC free article] [PubMed]